Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04246047 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04246047 · ClinicalTrials.gov record · last posted 2026-04-23

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Study acronym: DREAMM 7
StatusActive, Not Recruiting
PhasePhase 3
Started2020-05-07
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.

Amendment record 40 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 40 times since 2020-01-27; most recent amendment 2026-04-03. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2021-07-21
Status change Recruiting→Active, Not Recruitingv27
2020-05-15
Status change Not Yet Recruiting→Recruitingv5
Trial Details
NCT Number NCT04246047
Lead Sponsor GlaxoSmithKline
Conditions Multiple Myeloma
Enrollment 494 participants
Start Date 2020-05-07
Primary Completion 2023-10-02 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-23